New obesity drug AMG 786 begins first human safety tests

NCT ID NCT05406115

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested the safety of a new drug called AMG 786 in 65 healthy adults and people with obesity. Participants received either the drug or a placebo tablet, and researchers monitored for side effects and how the drug moves through the body. The goal was to see if AMG 786 is safe enough for further study, not to measure weight loss.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AMG 786 (oral tablet)
What this could lead to: If successful, this could point toward a new weight-loss medication for obesity.
What could go wrong: This is a very early Phase 1 trial focused only on safety, not weight loss. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

Clinical Pharmacology of Miami, LLC

Miami, Florida, 33014, United States
Orange County Research Center

Tustin, California, 92780, United States
Translational Clinical Research LLC

Aventura, Florida, 33180, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.